Next Article in Journal
Immunological Analysis of People in Northeast China after SARS-CoV-2 Inactivated Vaccine Injection
Next Article in Special Issue
Oral Peptide Vaccine against Hookworm Infection: Correlation of Antibody Titers with Protective Efficacy
Previous Article in Journal
“Vaccinate, Do Not Hesitate!”. Vaccination Readiness against COVID-19 among Polish Nursing Undergraduate Students: A National Cross-Sectional Survey
Previous Article in Special Issue
Australia’s Role in Pneumococcal and Human Papillomavirus Vaccine Evaluation in Asia-Pacific
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 9
Issue 9
10.3390/vaccines9091030
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

A Review of Australian Tick Vaccine Research

by
Ala E. Tabor
1,2
1
Queensland Alliance for Agriculture & Food Innovation, Centre for Animal Science, The University of Queensland, 306 Carmody Road, St. Lucia, QLD 4072, Australia
2
School of Chemistry and Molecular Biosciences, The University of Queensland, 68 Cooper Road, St. Lucia, QLD 4072, Australia
Vaccines 2021, 9(9), 1030; https://doi.org/10.3390/vaccines9091030
Submission received: 15 July 2021 / Revised: 6 September 2021 / Accepted: 8 September 2021 / Published: 16 September 2021
(This article belongs to the Special Issue Vaccines Development in Australia)
Review Reports Versions Notes

Abstract

:
Tick vaccine research in Australia has demonstrated leadership worldwide through the development of the first anti-tick vaccine in the 1990s. Australia’s Commonwealth Scientific and Industrial Research Organisation’s (CSIRO) research led to the development of vaccines and/or precursors of vaccines (such as crude extracts) for both the cattle tick and the paralysis tick. CSIRO commercialised the Bm86 vaccine in the early 1990s for Rhipicephalus australis; however, issues with dosing and lack of global conservation led to the market closure of Tick-GARD in Australia. New research programs arose both locally and globally. The Australian paralysis tick Ixodes holocyclus has perplexed research veterinarians since the 1920s; however, not until the 2000s did biotechnology exist to elucidate the neurotoxin—holocyclotoxin family of toxins leading to a proof of concept vaccine cocktail. This review revisits these discoveries and describes tributes to deceased tick vaccine protagonists in Australia, including Sir Clunies Ross, Dr Bernard Stone and Dr David Kemp.

1. Introduction

Ticks are hematophagous (bloodsucking) arthropods, which have evolved with animal hosts. There are 70 known tick species in Australia, and of these, 14 are soft ticks (Argasidae), and 56 are hard ticks (Ixodidae). Sixteen species are known to feed on humans and domestic animals, while the remaining species feed on wild mammals, birds and reptiles (reviewed by Barker et al., 2014) [1]. The hard tick species, which have the most economic impact on livestock and companion animals in Australia, are Rhipicephalus australis (the Australian cattle tick, formerly Rhipicephalus (Boophilus) microplus) and Ixodes holocyclus (paralysis tick).
The Australian cattle tick belongs to the cryptic species of R. microplus, which currently contains three species R. australis, R. annulatus and R. microplus, with three clades for the latter A, B and C [2,3]. Rhipicephalus australis has been found to be most similar to R. microplus Clade A, which appears to have a global distribution, including Asia, USA, Kenya and South America [2,4,5], and was introduced into northern Australia through the importation of infested Brahman cattle from Indonesia (Batavia) in 1872 [6]. Overall, the impact of the cattle tick on the global cattle industry was calculated at USD 22–30 billion per annum in 2016 and in Australia, approximately USD 160 million per annum in 2005 [7,8]. Although the Australasian species has been renamed as R. australis, this appears to be a geographic potentially continental species drift of the original species from India, which co-evolved with Bos indicus (tick resistant) breeds of cattle [9]. The global distribution and emigration of cattle worldwide perhaps have led to geographic separation of clades and species of R. microplus due to limited introductions, as reported for Australia described above [6,9]. Nonetheless, the species complex is distributed worldwide with far-reaching impacts on cattle production, as described.
Prior to the reinstatement of R. australis (Fuller 1899, [10]) in 2012–2014 [2,11], the species was previously referred to globally as Boophilus microplus and as R. (B.) microplus (reviewed by Barker et al. [1]). The University of Queensland (UQ) has led several relevant tick phylogenetic studies through Professor Stephen Barker’s research [1,12]. The microbiology research community requires a review of genus/species name changes or names of a newly discovered species by the International Committee on Systematics of Prokaryotes prior to publishing the accepted name on approved lists in the International Journal of Systematic and Evolutionary Biology. The journal also has strict guidelines for naming conventions and the use of sequence data (International Journal of Systematic and Evolutionary Microbiology—About | Microbiology Society (microbiologyresearch.org)). In parasitology, however, an author can suggest a new species or genus name; if the publication is accepted, the publication automatically sets the precedence for the use of a new genus/species name. Thus, the name changes for B. microplus have not been scrutinised by an international committee and, as such, remain controversial. For the purposes of this review, the accepted name of R. australis is used for the Australian research into the cattle tick, although the original publications refer to B. microplus or R. (B.) microplus.
The Australian paralysis tick Ixodes holocyclus is an indigenous tick species and is distributed along the east coast of Australia [13]. Unlike R. australis, I. holocyclus has remained the species name since it was first described by Neumann in 1899 [14]. Of the 892 species of ticks worldwide, approximately 27 species are evidenced as causing host paralysis, including two species in Australia, I. holocyclus and Ixodes cornuatus [15]. Ixodes holocyclus has been considered the most toxigenic tick species, producing a family of neurotoxins known as holocyclotoxins, which is currently the only toxin family to date described for a toxin-producing tick species [16]. Unlike the cattle tick R. microplus, which is a one host tick species specific to cattle to complete their life cycle, I. holocyclus has a three-host life cycle, including hosts, such as Australian wildlife, and humans, livestock and companion animals as primary and incidental hosts, respectively [13]. It has been reported that approximately 10,000–100,000 animals are affected annually, with 5% deaths in affected livestock and companion animal pets [17].
Approaches for the development of anti-tick vaccines have been quite variable, particularly for R. microplus and R. australis globally. One approach has been to target gut-associated ‘concealed antigens’, which are usually not recognised by the host during natural infestation; however, when used as a vaccine antigen, the host’s antibodies attack the tick gut, disrupting the life cycle [18]. One disadvantage is that these vaccines require several boosts each year as tick challenge does not boost host responses to these types of antigens. Other vaccine approaches have focused on secreted salivary antigens, which conversely are assumed to be recognised by the host during the natural challenge and, thus, may potentially boost vaccine responses [19]. This is particularly relevant for tick species whose tick stages feed on their hosts for shorter periods, i.e., I. holocyclus [17,20]; however, these approaches have also been applied in the discovery of R. microplus antigens [19].
Australia has led the world in the development of anti-tick vaccines. The first anti-cattle tick recombinant vaccine was developed by researchers from Australia’s National Science agency—the Commonwealth Scientific and Industrial Research Organisation (CSIRO) in the late 1980s [18]. Attempts to develop a canine anti-paralysis tick vaccine were also reported in the 1980s in Australia through research, also originally led by CSIRO [20]. This review reports Australian research capacity in the development of anti-tick vaccines throughout the 19th–20th Century with considerable efforts from the 1980s to date.

2. Review Approach

A search using the PubMed database was undertaken with the following terms: ((tick) AND (ticks)) AND (vaccine)) AND (Australia). This search returned 112 articles. Articles that were not related to the topic were deleted (Australian authors, un-related vaccines), resulting in 65 references. Several of these references were reviews, or out of scope for this review, or were published by the same group from which selected articles were highlighted. Following this scrutiny, 20 articles from this search were utilised in this review (See Supplementary Table S1). Other references were added to format the introduction, and together with other article leads (including international tick vaccine research and historic publications), this led to a total of 96 references for this review. These also included Meat & Livestock Australia reports as a relevant source of information available on the website (https://www.mla.com.au/research-and-development/search-rd-reports/, accessed on 3 June 2021) and available online vaccine patents.

3. Tick Vaccine Research

Tick vaccine research in Australia has been supported since the 1980s for both the cattle tick and the Australian paralysis tick through several groups, see Table 1.

3.1. Cattle Tick

Early studies by Trager published in 1939 demonstrated that exposing guinea pigs to Dermacentor variabilis (American dog tick) larvae led to the protection from subsequent infestations, and the serum could be used to protect guinea pigs from infestation [33]. An experiment published in Nature in 1979 showed that Dermacentor andersoni tick gut extracts were protective in a cattle tick challenge trial [34]. This phenomenon was further investigated using gut extracts from R. australis ticks by two research groups in Australia—CSIRO and UQ; see summary in Table 1.

3.1.1. CSIRO Research~1979–2010

Bm86 was isolated from the midgut of R. australis ticks by researchers at CSIRO. Initially, experiments demonstrated the in vivo protection from tick challenge using crude extracts, followed by demonstrated protection using native Bm86 protein [21]. Bm86 was patented, and recombinant protein was produced in E. coli through a collaboration with a commercial company and was registered following field trials [22,35]. This product was released as TickGARD® in 1994, and a yeast Pichia pastoris expressed Bm86 was released in 1995 as TickGARD®PLUS. The yeast expressed Bm86 was shown to be more immunogenic due to glycan moieties added during protein synthesis in yeast (reviewed by Willadsen in an industry report [23]). This reflected the research undertaken by a Cuban group that used the CSIRO patented information to express Bm86 in Pichia pastoris, which was registered as GAVAC® in 1993. GAVAC®’s Bm86 antigen is administered as 100 µg per dose and is currently adjuvanted with Montanide ISA 50 V2 oil adjuvant (https://www.cigb.edu.cu/en/product/gavac-2/, accessed on 1 September 2021) TickGARD®PLUS was discontinued in Australia by 2010, yet GAVAC® continues to be produced. The main issue for discontinuation of TickGARD®PLUS was the need for 3–4 boosts per year, which was not adopted by the extensive Australian beef industry where mustering of cattle is undertaken only once per year. TickGARD®PLUS doses were 50 µg [35]; however, the adjuvant used is not publicly available.
Apart from the boosting requirements for Bm86 vaccines, the other issue associated with Bm86-based vaccines was that it was found not to be cross-protective in several other countries; see Table 2. Table 2 summarises the data compiled by Dr Peter Willadsen in an industry report [23], as well as published studies of efficacies using the GAVAC® Cuban Bm86 product for Columbia and the USA, and the use of local Campo Grande Bm86 sequence tested in trials in Brazil.
During the development of the Bm86 vaccine, other purified mixtures of native tick proteins were also shown to be protective in vaccination trials [47]. Some of these vaccine antigens were further researched by the CSIRO group as novel antigens and/or also as a cocktail vaccine, including Bm86; see Table 3. This notion was suggested following the registration of Bm86 to find extra antigen(s), which may potentially improve the vaccine [34]. Some experimental trials were also undertaken in sheep, which were initially thought to be a cheaper model for the preliminary testing of novel vaccine antigens for cattle. Bm91 was an additional ‘concealed’ antigen isolated in 1994 and was thought to be an angiotensin-converting enzyme-like protein [48]. A combination vaccine including Bm86 and Bm91 was tested in 1996, demonstrating marginal improvement to Bm86 efficacies [49]. Bm91 was later determined to function as a putative carboxypeptidase [50]. A mucin-like glycoprotein was isolated from fractions following the removal of Bm86 and Bm91 and tested as native protein alone and in combination with Bm86 [51]. BMA7 had moderate effects when used alone as a vaccine and was demonstrated to improve the efficacy of Bm86 alone; see Table 3. Vitellin and vitellogenin vaccinations using native proteins produced good efficacies with a 66–68% reduction in tick larvae; however, the corresponding bacterial recombinant GP80 protein did not demonstrate any efficacies [52]. The efficacy of recombinant 5′ nucleotidase in sheep was reported at 73%, which was lower than Bm86 (85%); however, nil efficacy was reported in cattle for 5′ nucleotidase. In addition, vaccination using both 5′ nucleotidase and Bm86 did not demonstrate an improvement to Bm86 vaccination alone tested in cattle trials [53]. These results demonstrated that sheep are not viable model hosts for use in anti-cattle tick vaccine studies and that the application of a dual vaccine does not always lead to increased efficacies [53].
The majority of the above antigens were tested as native proteins and/or as bacterial recombinant proteins. In many cases, the antigen sequences were identified using N-terminal sequencing of the protein fractions under study. Thus, several of the above publications focused on the fractionation and purification of native proteins in preparation for vaccination and also for sequence analysis. It is thus not known if these proteins may be more efficacious if expressed in yeast.

3.1.2. UQ Research~1988–1999

Research at UQ was undertaken simultaneously as the above research by CSIRO in the 1990s. The researchers demonstrated success with using gut membrane extract and demonstrated protection of Bos taurus Hereford cattle from a subsequent challenge; see Table 1. Soluble gut antigens were shown not to be protective [24]. The research did not progress further to produce specific vaccine candidates; however, it published useful immunological studies, such as the demonstrated correlation of IgG1 and complement for protection from tick challenge, which underpinned future research (see Section 3.1.3). The research ceased when the lead scientist at the Department of Parasitology, Dr Joan Opdebeeck, left UQ in the late 1990s.

3.1.3. Cooperative Research Centre for Beef Genetic Technologies (Beef CRC) 2005–2012; Meat & Livestock Australia (MLA) 2014–2021

Due to the above reported variable efficacies of Bm86-based vaccines as well as the need to boost 3–4 times per year, a new research team commenced within the Beef CRC, which included the Queensland Department of Agriculture & Fisheries (QDAF, previously Department of Primary Industries & Fisheries/DPI&F and Department of Employment, Economic Development & Innovation/DEEDI), Murdoch University’s Centre for Comparative Genomics and the US Department of Agriculture as the main research partners. The team employed a reverse vaccinology approach by screening a database of R. microplus EST sequences (n = 13,643) and by undertaking gene discovery experiments to identify transcripts from host sensing and feeding of different tick life cycle stages of R. australis [54,55,56]. B cell epitopes of selected candidates were screened in ELISAs using serum from tick susceptible and resistant Santa Gertrudis composite breed cattle [57]. Epitopes recognised by resistant cattle sera were tested in an in vitro adult female tick assay by antibody feeding [58]. Mixtures of epitopes showing high efficacies in antibody tick feeding screens were tested in tick challenge cattle trials, and the individual antigens from successful mixtures were subsequently tested in cattle trials, and this testing was completed in 2017 [26]. Nine candidates were subsequently submitted as full patents, and a recent longevity trial demonstrated high increasing efficacies 6 months after the initial dual vaccination using a dual antigen vaccine (MLA report, unpublished). Commercial interest has yet to be gauged by the Intellectual Property owners, and, as such, further specific details cannot be provided in this review.

3.2. Paralysis Tick

Early research in the 1920s by Sir Ian Clunies Ross determined the protection from tick paralysis by using crude salivary gland extracts from I. holocyclus adult female ticks [59]. Treatment of paralysis using serum from hyperimmune dogs was also demonstrated early last century [60]. The toxin fraction from the salivary glands of adult female ticks was first ascertained by Kaire in 1966 [61]. These seminal studies provided the background for future research, characterising a family of neurotoxins enabled only by developments in modern biotechnologies, such as proteomics and transcriptomics. Although other tick species are known to cause paralysis in other countries, i.e., Rhipicephalus evertsi evertsi (lamb paralysis, South Africa), Argas (Persicargus) walkerae (poultry paralysis, South Africa), Dermacentor variabilis (dog paralysis in the USA), the causative proteins or toxins are yet to be elucidated at the molecular level [62,63,64].

3.2.1. CSIRO Research 1980s

Several studies were undertaken by Dr Bernard Stone and colleagues at CSIRO, including attempts to isolate the causative toxin(s) [17,65,66]. These studies concluded that the toxin was in the size range of 40–80 kDa as representative of the toxic fractions dissected from whole ticks or adult female salivary glands. This result reflected research identifying toxin fractions from R. evertsi evertsi and A. (P.) walkerae, which were reported to be similar in size [64]. As mentioned in Table 1, this group developed assays for screening toxin fractions, which underpinned future research in this field. Although partially purified toxin extracts from I. holocyclus treated with glutaraldehyde showed good anti-toxin responses [67], the practicality of preparing native tick material was not feasible for vaccine development. The term holocyclotoxin was coined by Stone and co-workers, and although mentioned in earlier publications, the 1986 publication used the term officially in the journal’s title [67].

3.2.2. University of Technology Sydney (UTS) Research 1990s

The above research of Stone and colleagues overlapped with research undertaken by Associate Professor Kevin Broady and colleagues at UTS, who were also attempting to isolate the causative paralysing holocyclotoxins. Three holocyclotoxins HT-1, HT-2 and HT-3 were isolated from rat brain synaptosomes (pinched off nerve terminals), which bind the neurotoxins in a temperature-dependent manner [31]. These polypeptides had a molecular mass of 5 kDa, and the HT-1 gene was isolated using PCR technologies in 1992. A recombinant HT-1 was produced and shown to be immunogenic; however, the native sequences of HT-2 and HT-3 were not characterised. It was not certain whether the genes were distinct or whether they were post-translational modified forms of HT-1 (reviewed by Masina and Broady 1999) [32]. Thus, as mentioned above, the large HT family had yet to be characterised at the molecular level.

3.2.3. UQ Research 2000s

Approximately 17 years following the initial description of HT-1 and research program commenced at UQ, which aimed to sequence the transcriptome of I. holocyclus, gut and salivary gland organs from paralysed companion animals were collected from Veterinary Surgeries from the broader Brisbane area. Two different pooled organ samples were sequenced from guts and salivary glands using Illumina short-read technology, and a family of ~19 HTs (including the initial HT-1 described above) were characterised with amino acid identities ranging between 38% and 99% [16]. A proof-of-concept dog trial of a cocktail of HTs was undertaken and showed protection from I. holocyclus tick challenge (unpublished). Commercialisation through a local tick antiserum company in Australia is currently underway (author corporate knowledge).

3.3. Australian Researchers (Deceased) Who Made Significant Impacts into Tick Vaccine Research

During the process of this review, it was clear that several researchers in Australia were responsible for seminal studies, which led to the development of the current vaccines against cattle ticks and paralysis ticks. These researchers were mostly employed by CSIRO, and their research legacy paved the way for tick vaccine development in Australia. Each of these three researchers was dedicated to science until they passed with phenomenal legacies.

3.3.1. Sir Dr Ian Clunies Ross (1899–1959)

Dr Ian Clunies Ross completed a bachelor’s degree in veterinary science (B.V.Sc.) at the University of Sydney in 1921. Clunies Ross spent 1921 as a temporary lecturer in veterinary anatomy at the university, and in 1922, he was appointed as a Walter and Eliza Hall research fellow. In England, he studied parasites at the Molteno Institute, Cambridge and at the London School of Tropical Medicine. In 1925, he resumed research on parasites and undertook some part-time teaching at the University of Sydney’s Veterinary School (https://adb.anu.edu.au/biography/clunies-ross-sir-william-ian-9770, accessed on 1 September 2021) He was employed as a parasitologist at the Council for Scientific and Industrial Research (CSIR—later CSIRO) in the mid1920s. His pioneering research in the paralysis tick laid the foundation for ongoing research into the toxic fractions of the Australian paralysis tick I. holocyclus, as described above [59,68,69]. Sir Dr Ian Clunies Ross’s publications have been previously summarized [70]. The review by Gordon was included in a special issue dedicated to Sir Dr Ian Clunies Ross in Volume 44, Issue 10 (October 1968) of the Australian Veterinary Journal. His research interests included the hydatid parasite Echinococcus granulosis and the liver fluke Fasciola hepatica, with a strong research focus associated with the development of livestock antihelmintic treatments (see citations in Gordon 1968 [70]). During his research career, he published approximately 70 research publications, including surveys and records, immunity and resistance, pathogenesis, antihelmintics and the application of control measures across many livestock parasite species [70]. In 1954, Clunies Ross was knighted and appointed CMG (Order of St Michael and St George) and became a Foundation Fellow of the Australian Academy of Science. He also held administrative leadership roles as the Chairman of CSIRO from 1946 (formerly CSIR) until his passing in 1959.

3.3.2. Dr Bernard F. Stone (1926–2005) (Marian Schneid, Personal Communication)

In 1954, Bernard Stone joined CSIRO, Division of Entomology, working on cattle tick biocide resistance, and authored his first article about parthenogenesis in the cattle tick in 1963 [71]. He completed his BSc and Master of Science (MPhil) at UQ by 1966 and his PhD with the University of Western Ontario (Canada) by 1968. Dr Stone was awarded a UQ Doctor of Science in 1982. As a researcher, he was quite prolific with 90 research publications (Marian Schneid, personal communication) with a strong impact on the development of I. holocyclus toxoid and the standardisation of tick anti-toxin production in Australia for treating paralysis in domestic pets and livestock [17,27,29,67,72]. His publications also focused on R. australis drug resistance [73,74,75]. In 1994, he was awarded an Order of Australia for his contributions to science, environment, youth and scouting. Following retirement, he led a consultancy business evaluating commercial antitoxins for tick paralysis until his passing in 2005.

3.3.3. Dr David H. Kemp (1940–2007) (Dr Anne Kemp, Personal Communication)

After completing his PhD on Ixodes ricinus ticks on sheep in Scotland at The University of Edinburgh, Dr Kemp was employed by CSIRO in Australia with the Division of Animal Health. Dr Kemp had an extensive career in cattle tick research with CSIRO, spanning almost 40 years, and he was one of the main protagonists developing the CSIRO TickGARD vaccine [18,21,76]. He also collaborated with Allen, who initially discovered the protective properties of Dermacentor variabilis tick gut extracts in 1979 [34,77]. Specifically, together with his technician Joanne Gough, he noted that tick-resistant breeds of cattle carried ticks, which appeared as hemorrhages internally (red legs) (Dr Anne Kemp, personal communication). He was a tick biologist with many interests: improving cattle resistance to ticks, tick histological structure, the taxonomy of Australian ticks (his collection is currently within CSIRO’s Australian Insect Collection, Canberra; Australian National Insect Collection-CSIRO) and leading ACTEST—tick acaricide testing facility (Note by author: ACTEST was transferred to QDAF in the 2000s). Approximately 60 of Dr Kemp’s publications are recorded in NCBI’s PubMed (searched 12/07/2021), mostly associated with R. australis (as B. microplus), with additional research contributions to I. holocyclus associated with livestock infestations [78,79,80], and other tick/ectoparasite species [81,82]. Research collaboration between Dr Kemp and Dr Stone (as members of different Divisions in CSIRO) was demonstrated with the development of an in vitro feeding system for I. holocyclus toxin collection [28].
Dr Kemp also contributed to the commencement of the new Beef CRC/MLA research program (Section 3.1.3) (during his retirement) through his initial suggestions to examine ‘frustrated ticks’ (ticks in bags sensing the cattle host) in vaccine candidate discovery research. This led to vaccine candidates, which were included in the reverse vaccinology approach by identifying transcripts produced when sensing cattle [55,56]; see Table 1.

3.4. Current Status of Global Cattle Tick Vaccine Research

Several cattle tick vaccine candidates have been patented, and these candidates were recently reviewed by Tabor [83] and will not be re-reviewed here. Currently, CATVAC (cattle tick vaccine consortium) is testing several of these antigens in trials in Morocco funded through the Bill & Melinda Gates Foundation in an effort to identify a globally applicable cattle tick vaccine [43]. These include:

3.4.1. Bm86 and Subolesin

Bm86 and Subolesin as a dual vaccine (100 µg per antigen), was delivered in a double emulsion to cattle using three boosts, which has shown a 97% reduction in tick numbers [84] following challenge with a Mexican R. microplus and a Texan R. annulatus strains. The Bm86 sequence was based on the Mexican R. microplus sequence; thus, the experiment represented a homologous Bm86 challenge. Subolesin (ortholog of ankyrin in ticks) was identified as a tick protective antigen in I. scapularis ticks [85], and the R. microplus homologue was shown to protect ~60% efficacy in cattle [86]. It is currently not known if the variation in Bm86 efficacies (Table 2 above) will impact the commercialisation of this vaccine.

3.4.2. Aquaporin

Aquaporin, a water-conducting channel, was suggested as a vaccine candidate for the blood fluke Schistosoma japonicum with several predicted immunogenic epitopes and an integral transmembrane structure [87]. RNA interference studies demonstrated a strong knockdown effect on the R. microplus aquaporin homologue, and a 73% efficacy was confirmed following cattle trial vaccination using three boosts of 100 µg recombinant protein in a Montanide ISA 61 VG adjuvant and tick challenge [88].

3.4.3. 60S Acidic Ribosomal Peptide P0

P0 has demonstrated 96% efficacy against R. microplus in cattle trials in Cuba using four doses of 250 µg of peptide in VG Montanide 888 adjuvant prior to challenge [89]. P0 was previously shown to be lethal in RNA interference studies in a tick Haemaphysalis longicornis [90]. It is likely that the peptide production of a bovine vaccine has stalled the commercialisation of this candidate.

3.4.4. Ferritin-2

Ferritin-2 has shown promise as a vaccine candidate (three doses of 100 µg prior to tick challenge) in I. ricinus (rabbits with Incomplete Freund’s adjuvant) and also R. microplus (cattle with Montanide ISA 50V adjuvant) with 96% and 64% efficacies, respectively [91]. The candidate was discovered when studying iron homeostasis in I. ricinus was found to be essential in tick feeding.

4. Conclusions

It is clear that, in particular, due to the commercialisation of the cattle tick Bm86 protein, vaccination against ticks is a feasible control option [34]. The research by CSIRO described the impact of Australian research on the development of anti-tick vaccines. For I. holocyclus, a vaccine alternative to companion animal chemical treatments is also a future option for this unique Australian ectoparasite. This author notes that due to the focused impact of this tick species on the east coast of Australia, international animal health companies deem that commercialisation is not economically feasible. With the shortcomings associated with R. microplus/R. australis delivery, both with poor global efficacies and the need for multiple boosting, much research has focused on identifying alternative vaccine candidates, as described above. What is disconcerting is the slow commercialisation of promising new cattle tick vaccine candidates, a topic recently reviewed by de la Fuente and Estrada-Pena in 2019 [92]. Indeed, of the anti-cattle tick vaccines described in this review, only the Bm86 antigen vaccine GAVAC® is currently commercially available. De la Fuente and Estrada-Pena discuss the challenges associated with the fact that the application of generic chemicals is a more attractive alternative to specific vaccines (confirmed by the author’s personal experience with R. australis vaccine commercialisation as companies strive to develop generic chemicals as alternatives to vaccines); the expense of novel adjuvant delivery systems for livestock; the challenge to produce anti-tick vaccines that can be applied across multiple tick species; and finally, the ability to control tick-vectored pathogens simultaneously [92]. It remains to be seen if new products will become available to the market. Vaccines will always provide a safe alternative to chemicals by reducing environmental residues and costs in the administration of these chemicals.

Supplementary Materials

The following is available online at The following are available online at https://www.mdpi.com/article/10.3390/vaccines9091030/s1, Table S1: Categories of articles retrieved following a systematic PubMed search of tick vaccine articles in Australia.

Funding

This research received no external funding.

Acknowledgments

The author acknowledges receiving historical contributions associated with Stone and Kemp from family members Marian Schneid and Anne Kemp, respectively.

Conflicts of Interest

The author declares no conflict of interest.

References

  1. Barker, S.C.; Walker, A.R.; Campelo, D. A list of the 70 species of Australian ticks diagnostic guides to and species accounts of Ixodes holocyclus (paralysis tick), Ixodes cornuatus (southern paralysis tick) and Rhipicephalus australis (Australian cattle tick); and consideration of the place of Australia in the evolution of ticks with comments on four controversial ideas. Int. J. Parasitol. 2014, 44, 941–953. [Google Scholar] [CrossRef]
  2. Burger, T.D.; Shao, R.; Barker, S.C. Phylogenetic analysis of mitochondrial genome sequences indicates that the cattle tick, Rhipicephalus (Boophilus) microplus, contains a cryptic species. Mol. Phylogenet. Evol. 2014, 76, 241–253. [Google Scholar] [CrossRef]
  3. Low, V.L.; Tay, S.T.; Kho, K.L.; Koh, F.X.; Tan, T.K.; Lim, Y.A.L.; Ong, B.L.; Panchadcharam, C.; Norma-Rashid, Y.; Sofian-Azirun, M. Molecular characterisation of the tick Rhipicephalus microplus in Malaysia: New insights into the cryptic diversity and distinct genetic assemblages throughout the world. Parasit. Vectors 2015, 8, 341–351. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Encinosa Guzmán, P.E.; Fernández Cuétara, C.; Cano Argüelles, A.L.; Fuentes Castillo, A.; García Martínez, Y.; Rodríguez Fernández, R.; Fernández Afonso, Y.; Bello Soto, Y.; González Alfaro, Y.; Méndez, L.; et al. Characterization of two Cuban colonies of Rhipicephalus microplus ticks. Vet. Parasitol. Reg. Stud. Rep. 2021, 25, 100591. [Google Scholar] [CrossRef]
  5. Kanduma, E.G.; Emery, D.; Githaka, N.W.; Nguu, E.K.; Bishop, R.P.; Šlapeta, J. Molecular evidence confirms occurrence of Rhipicephalus microplus Clade A in Kenya and sub-Saharan Africa. Parasit. Vectors 2020, 13, 432–447. [Google Scholar] [CrossRef] [PubMed]
  6. Gee, G.F. The Economic Importance of Cattle Tick in Australia; Bureau of Agricultural Economics: Canberra, Australia, 1959.
  7. Lew-Tabor, A.E.; Rodriguez Valle, M. A review of reverse vaccinology approaches for the development of vaccines against ticks and tick borne diseases. Ticks Tick Borne Dis. 2016, 7, 573–585. [Google Scholar] [CrossRef]
  8. Sackett, D.; Holmes, P.; Abbott, K.; Jephcott, S.; Barber, M. Assessing the Economic Cost of Endemic Disease on the Profitability of Australia Beef Cattle and Sheep Producers; Meat & Livestock Australia: Sydney, Australia, 2006. [Google Scholar]
  9. Ajmone-Marsan, P.; Garcia, J.F.; Lenstra, J.A. On the origin of cattle: How aurochs became cattle and colonized the world. Evol. Anthr. Issues News Rev. 2010, 19, 148–157. [Google Scholar] [CrossRef]
  10. Fuller, C. Notes on the Queensland cattle tick and its relationship to the red water tick and the blue tick of Cape Colony (South Africa). QLD Agric. J. 1899, 4, 389–394. [Google Scholar]
  11. Estrada-Pena, A.; Venzal, J.M.; Nava, S.; Mangold, A.; Guglielmone, A.; Labruna, M.B.; de la Fuente, J. Reinstatement of Rhipicephalus (Boophilus) australis (Acari: Ixodidae) with redescription of the adult and larval stages. J. Med. Entomol. 2012, 49, 794–802. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Barker, S.; Murrell, A. Systematics and evolution of ticks with a list of valid genus and species names. Parasitology 2004, 129, S15–S36. [Google Scholar] [CrossRef] [PubMed]
  13. Jackson, J.; Beveridge, I.; Chilton, N.B.; Andrews, R.H. Distributions of the paralysis ticks Ixodes cornuatus and Ixodes holocyclus in south-eastern Australia. Aust. Vet. J. 2007, 85, 420–424. [Google Scholar] [CrossRef]
  14. Neumann, G. Revision de la Famille des Ixodides. In Memoires de la Societe Zoologique de France; Au Siege de la Société: Paris, France, 1899; pp. 107–294. [Google Scholar]
  15. Mans, B.J.; Neitz, A.W.H. Adaptation of ticks to a blood-feeding environment: Evolution from a functional perspective. Insect. Biochem. Mol. Biol. 2004, 34, 1–17. [Google Scholar] [CrossRef]
  16. Rodriguez-Valle, M.; Moolhuijzen, P.; Barrero, R.A.; Ong, C.T.; Busch, G.; Karbanowicz, T.; Booth, M.; Clark, R.; Koehbach, J.; Ijaz, H.; et al. Transcriptome and toxin family analysis of the paralysis tick, Ixodes Holocyclus. Int. J. Parasitol. 2018, 48, 71–82. [Google Scholar] [CrossRef] [Green Version]
  17. Stone, B.; Aylward, J. Tick toxicoses and the causal toxins: Tick paralysis. In Progress in Venom and Toxin Reseach. Proceedings of the First Asia-Pacific Congress on Animal, Plant and Microbial Toxins; National University of Singapore: Singapore, 1987. [Google Scholar]
  18. Kemp, D.H.; Pearson, R.D.; Gough, J.M.; Willadsen, P. Vaccination against Boophilus microplus: Localization of antigens on tick gut cells and their interaction with the host immune system. Exp. Appl. Acarol. 1989, 7, 43–58. [Google Scholar] [CrossRef]
  19. Maruyama, S.R.; Garcia, G.R.; Teixeira, F.R.; Brandão, L.G.; Andersen, J.M.; Ribeiro, J.M.C.; Valenzuela, J.G.; Horackova, J.; Veríssimo, C.J.; Katiki, L.M.; et al. Mining a differential sialotranscriptome of Rhipicephalus microplus guides antigen discovery to formulate a vaccine that reduces tick infestations. Parasit. Vectors 2017, 10, 206–222. [Google Scholar] [CrossRef] [PubMed]
  20. Stone, B.F.; Neish, A.L.; Wright, I.G. Immunization of rabbits to produce high serum titres of neutralizing antibodies and immunity to the paralyzing toxin of Ixodes Holocyclus. Aust. J. Exp. Biol. Med. Sci. 1982, 60 Pt 4, 351–358. [Google Scholar] [CrossRef]
  21. Kemp, D.H.; Agbede, R.I.; Johnston, L.A.; Gough, J.M. Immunization of cattle against Boophilus microplus using extracts derived from adult female ticks: Feeding and survival of the parasite on vaccinated cattle. Int. J. Parasitol. 1986, 16, 115–120. [Google Scholar] [CrossRef]
  22. Rand, K.N.; Moore, T.; Sriskantha, A.; Spring, K.; Tellam, R.; Willadsen, P.; Cobon, G.S. Cloning and expression of a protective antigen from the cattle tick Boophilus Microplus. Proc. Natl. Acad. Sci. USA 1989, 86, 9657–9661. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Willadsen, P. The Development of a New or Improved Vaccine against Boophilus Microplus: Opportunities for R&D Investment; Meat & Livestock Australia: Sydney, Australia, 2008. [Google Scholar]
  24. Opdebeeck, J.P.; Wong, J.Y.; Jackson, L.A.; Dobson, C. Hereford cattle immunized and protected against Boophilus microplus with soluble and membrane-associated antigens from the midgut of ticks. Parasite Immunol. 1988, 10, 405–410. [Google Scholar] [CrossRef] [PubMed]
  25. Jackson, L.A.; Opdebeeck, J.P. Humoral immune responses of Hereford cattle vaccinated with midgut antigens of the cattle tick, Boophilus microplus. Parasite Immunol. 1990, 12, 141–151. [Google Scholar] [CrossRef] [PubMed]
  26. Tabor, A.; Rodriguez Valle, M.; McGowan, M.; Mayer, D.; Fowler, E.; Minchin, M.; Zhang, B. Cattle Vaccination Studies Using Novel Anti-Cattle Tick Antigens Developed during Beef CRC Research; B.AHE.0212 Final Report; Meat & Livestock Australia: Sydney, Australia, 2017. [Google Scholar]
  27. Stone, B.F.; Neish, A.L. Tick-paralysis toxoid: An effective immunizing agent against the toxin of Ixodes Holocyclus. Aust. J. Exp. Biol. Med. Sci. 1984, 62 Pt 2, 189–191. [Google Scholar] [CrossRef]
  28. Stone, B.F.; Commins, M.A.; Kemp, D.H. Artificial feeding of the Australian paralysis tick, Ixodes holocyclus and collection of paralysing toxin. Int. J. Parasitol. 1983, 13, 447–454. [Google Scholar] [CrossRef]
  29. Stone, B.F.; Cowie, M.R.; Kerr, J.D.; Binnington, K.C. Improved toxin/antitoxin assays for studies on the Australian paralysis tick Ixodes Holocyclus. Aust. J. Exp. Biol. Med. Sci. 1982, 60, 309–318. [Google Scholar] [CrossRef]
  30. Wright, I.G.; Stone, B.F.; Neish, A.L. Tick (Ixodes holocyclus) paralysis in the dog—Induction of immunity by injection of toxin. Aust. Vet. J. 1983, 60, 69–70. [Google Scholar] [CrossRef]
  31. Thurn, M.J.; Gooley, A.; Broady, K.W. Identification of the neurotoxin from the Australian paralysis tick, Ixodes holocyclus. Toxicon 1992, 30, 557. [Google Scholar] [CrossRef]
  32. Masina, S.; Broady, K.W. Tick paralysis: Development of a vaccine. Int. J. Parasitol. 1999, 29, 535–541. [Google Scholar] [CrossRef]
  33. Trager, W. Acquired immunity to ticks. J. Parasitol. 1939, 25, 57–81. [Google Scholar] [CrossRef]
  34. Allen, J.R.; Humphreys, S.J. Immunisation of guinea pigs and cattle against ticks. Nature 1979, 280, 491–493. [Google Scholar] [CrossRef] [PubMed]
  35. Willadsen, P.; Bird, P.; Cobon, G.S.; Hungerford, J. Commercialisation of a recombinant vaccine against Boophilus Microplus. Parasitology 1995, 110, S43–S50. [Google Scholar] [CrossRef] [PubMed]
  36. Tellam, R.L.; Smith, D.; Kemp, D.H.; Willadsen, P. Vaccination against ticks. In Animal Parasite Control Utilizing Biotechnology; Yong, W.K., Ed.; CRC Press Inc.: Boca Raton, FL, USA, 1992; pp. 303–331. [Google Scholar]
  37. García-García, J.C.; Gonzalez, I.L.; González, D.M.; Valdés, M.; Méndez, L.; Lamberti, J.; D’Agostino, B.; Citroni, D.; Fragoso, H.; Ortiz, M.; et al. Sequence variations in the Boophilus microplus Bm86 locus and implications for immunoprotection in cattle vaccinated with this antigen. Exp. Appl. Acarol. 1999, 23, 883–895. [Google Scholar] [CrossRef]
  38. Cobon, G.S. An anti-arthropod vaccine: TickGARD—A vaccine to prevent cattle tick infestations. In New Generation Vaccines; Levine, M.M., Woodrow, G.C., Kaper, J.B., Cobon, G.S., Eds.; Marcel Dekker Inc.: New York, NY, USA; Basel, Switzerland; Hong Kong, China, 1997; pp. 1145–1151. [Google Scholar]
  39. Rodríguez, M.; Rubiera, R.; Penichet, M.; Montesinos, R.; Cremata, J.; Falcón, V.; Sánchez, G.; Bringas, R.; Cordovés, C.; Mario Valdés, M.; et al. High level expression of the B. microplus Bm86 antigen in the yeast Pichia pastoris forming highly immunogenic particles for cattle. J. Biotechnol. 1994, 33, 135–146. [Google Scholar] [CrossRef]
  40. Montesino, R.; Cremata, J.; Rodriguez, M.; Besada, V.; Falcon, V.; de la Fuente, J. Biochemical characterization of the recombinant Boophilus microplus Bm86 antigen expressed by transformed Pichia pastoris cells. Biotechnol. Appl. Biochem. 1996, 23, 23–28. [Google Scholar] [CrossRef] [PubMed]
  41. Canales, M.; Almazán, C.; Naranjo, V.; Jongejan, F.; de la Fuente, J. Vaccination with recombinant Boophilus annulatus Bm86 ortholog protein, Ba86, protects cattle against B. annulatus and B. microplus infestations. BMC Biotechnol. 2009, 9, 29. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Patarroyo, J.H.; Portela, R.W.; De Castro, R.O.; Couto Pimentel, J.; Guzman, F.; Patarroyo, M.E.; Vargas, M.I.; Prates, A.A.; Dias Mendes, M.A. Immunization of cattle with synthetic peptides derived from the Boophilus microplus gut protein (Bm86). Vet. Immunol. Immunopathol. 2002, 88, 163–172. [Google Scholar] [CrossRef]
  43. Schetters, T.; Bishop, R.; Crampton, M.; Kopáček, P.; Lew-Tabor, A.; Maritz-Olivier, C.; Miller, R.; Mosqueda, J.; Patarroyo, J.; Rodriguez-Valle, M.; et al. Cattle tick vaccine researchers join forces in CATVAC. Parasit. Vectors 2016, 9, 105–112. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Freeman, J.M.; Davey, R.B.; Kappmeyer, L.S.; Kammlah, D.M.; Olafson, P.U. Bm86 midgut protein sequence variation in South Texas cattle fever ticks. Parasit. Vectors 2010, 3, 101–109. [Google Scholar] [CrossRef] [Green Version]
  45. Cunha, R.C.; Pérez de León, A.A.; Leite, F.P.; Pinto Lda, S.; Dos Santos Júnior, A.G.; Andreotti, R. Bovine immunoprotection against Rhipicephalus (Boophilus) microplus with recombinant Bm86-Campo Grande antigen. Rev. Bras. Parasitol. Vet. 2012, 21, 254–262. [Google Scholar] [CrossRef] [Green Version]
  46. Andreotti, R.; Pedroso, M.S.; Caetano, A.R.; Martins, N.F. Comparison of predicted binders in Rhipicephalus (Boophilus) microplus intestine protein variants Bm86 Campo Grande strain, Bm86 and Bm95. Rev. Bras. Parasitol. Vet. 2008, 17, 93–98. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  47. Willadsen, P.; Kemp, D.H. Vaccination with ‘concealed’ antigens for tick control. Parasitol. Today 1988, 4, 196–198. [Google Scholar] [CrossRef]
  48. Riding, G.A.; Jarmey, J.; McKenna, R.V.; Pearson, R.; Cobon, G.S.; Willadsen, P. A protective “concealed” antigen from Boophilus microplus. Purification, localization, and possible function. J. Immunol. 1994, 153, 5158–5166. [Google Scholar]
  49. Willadsen, P.; Smith, D.O.N.; Cobon, G.; McKenna, R.V. Comparative vaccination of cattle against Boophilus microplus with recombinant antigen Bm86 alone or in combination with recombinant Bm91. Parasit. Immunol. 1996, 18, 241–246. [Google Scholar] [CrossRef]
  50. Jarmey, J.M.; Riding, G.A.; Pearson, R.D.; Mckenna, R.V.; Willadsen, P. Carboxydipeptidase from Boophilus microplus: A “concealed” antigen with similarity to angiotensin-converting enzyme. Insect. Biochem. Mol. Biol. 1995, 25, 969–974. [Google Scholar] [CrossRef]
  51. McKenna, R.V.; Riding, G.A.; Jarmey, J.M.; Pearson, R.D.; Willadsen, P. Vaccination of cattle against the Boophilus microplus using a mucin-like membrane glycoprotein. Parasit. Immunol. 1998, 20, 325–336. [Google Scholar] [CrossRef] [PubMed]
  52. Tellam, R.L.; Kemp, D.; Riding, G.; Briscoe, S.; Smith, D.; Sharp, P.; Irving, D.; Willadsen, P. Reduced oviposition of Boophilus microplus feeding on sheep vaccinated with vitellin. Vet. Parasitol. 2002, 103, 141–156. [Google Scholar] [CrossRef]
  53. Hope, M.; Jiang, X.; Gough, J.; Cadogan, L.; Josh, P.; Jonsson, N.; Wiladsen, P. Experimental vaccination of sheep and cattle against tick infestation using recombinant 5′-nucleotidase. Parasitol. Immunol. 2010, 32, 135–142. [Google Scholar] [CrossRef] [Green Version]
  54. Wang, M.; Guerrero, F.D.; Pertea, G.; Nene, V.M. Global comparative analysis of ESTs from the southern cattle tick, Rhipicephalus (Boophilus) Microplus. BMC Genom. 2007, 8, 368. [Google Scholar] [CrossRef] [Green Version]
  55. Lew-Tabor, A.E.; Moolhuijzen, P.M.; Vance, M.E.; Kurscheid, S.; Valle, M.R.; Jarrett, S.; Minchin, C.M.; Jackson, L.A.; Jonsson, N.N.; Bellgard, M.I.; et al. Suppressive subtractive hybridization analysis of Rhipicephalus (Boophilus) microplus larval and adult transcript expression during attachment and feeding. Vet. Parasitol. 2010, 167, 304–320. [Google Scholar] [CrossRef]
  56. Rodriguez-Valle, M.; Lew-Tabor, A.; Gondro, C.; Moolhuijzen, P.; Vance, M.; Guerrero, F.D.; Bellgard, M.; Jorgensen, W. Comparative microarray analysis of Rhipicephalus (Boophilus) microplus expression profiles of larvae pre-attachment and feeding adult female stages on Bos indicus and Bos taurus cattle. BMC Genom. 2010, 11, 437. [Google Scholar] [CrossRef] [Green Version]
  57. Piper, E.K.; Jonsson, N.N.; Gondro, C.; Vance, M.E.; Lew-Tabor, A.; Jackson, L.A. Peripheral cellular and humoral responses to infestation with the cattle tick Rhipicephalus microplus in Santa Gertrudis cattle. Parasit. Immunol. 2017, 39, e12402. [Google Scholar] [CrossRef] [Green Version]
  58. Lew-Tabor, A.E.; Bruyeres, A.G.; Zhang, B.; Rodriguez Valle, M. Rhipicephalus (Boophilus) microplus tick in vitro feeding methods for functional (dsRNA) and vaccine candidate (antibody) screening. Ticks Tick Borne Dis. 2014, 5, 500–510. [Google Scholar] [CrossRef] [PubMed]
  59. Ross, I.C. An experimental study of tick paralysis in Australia. Parasitology 1926, 18, 410–429. [Google Scholar] [CrossRef]
  60. Oxer, D.T.; Ricardo, C.L. Notes on the biology, toxicity and breeding of Ixodes holocyclus (Neumann). Aust. Vet. J. 1942, 18, 194–199. [Google Scholar] [CrossRef]
  61. Kaire, G.H. Isolation of tick paralysis toxin from Ixodes Holocyclus. Toxicon 1966, 4, 91–97. [Google Scholar] [CrossRef]
  62. Mans, B.J.; Gothe, R.; Neitz, A.W.H. Biochemical perspectives on paralysis and other forms of toxicoses caused by ticks. Parasitology 2004, 129, S95–S111. [Google Scholar] [CrossRef]
  63. Pienaar, R.; Neitz, A.W.H.; Mans, B.J. Tick paralysis: Solving an enigma. Vet. Sci. 2018, 5, 53. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  64. Gothe, R.; Kunze, K.; Hoogstraal, H. The mechanisms of pathogenicity in the tick paralyses. J. Med. Entomol. 1979, 16, 357–369. [Google Scholar] [CrossRef] [PubMed]
  65. Stone, B.F.; Neish, A.L.; Wright, I.G. Tick (Ixodes holocyclus) paralysis in the dog—Quantitative studies on immunity following artificial infestation with the tick. Aust. Vet. J. 1983, 60, 65–68. [Google Scholar] [CrossRef]
  66. Stone, B.F.; Doube, B.M.; Binnington, K.C.; Goodger, B.V. Toxins of the Australian paralysis tick Ixodes holocyclus. In Recent Advances in Acarology; Rodriguez, J.G., Ed.; Academic Press: Massachusetts, MA, USA, 1979; pp. 347–356. [Google Scholar]
  67. Stone, B.F.; Uren, M.F.; Neish, A.L.; Morrison, J.J. Toxoid stimulation in dogs of high titres of neutralising antibodies against holocyclotoxin, the paralysing toxin of the Australian paralysis tick Ixodes Holocyclus. Aust. Vet. J. 1986, 63, 125–127. [Google Scholar] [CrossRef]
  68. Ross, I. Tick paralysis: A fatal disease of dogs and other animals in Eastern Australia. J. Counc. Sci. Ind. Res. Aust. 1935, 8, 8–13. [Google Scholar]
  69. Ross, I.C. The bionomics of Ixodes holocyclus Neumann, with a redescription of the adult and nymphal stages and a description of the Larvae. Parasitology 1924, 16, 365–381. [Google Scholar] [CrossRef]
  70. Gordon, H. Ian Clunies Ross his publications and the enduring influence of his work. Aust. Vet. J. 1968, 44, 471–478. [Google Scholar] [CrossRef]
  71. Stone, B.F. Parthenogenesis in the cattle tick, Boophilus Microplus. Nature 1963, 200, 1233. [Google Scholar] [CrossRef]
  72. Stone, B.F.; Binnington, M.; Gauci, M.; Aylward, J.H. Tick/host interactions for Ixodes holocyclus: Role, effects, biosynthesis and nature of its toxic and allergenic oral secretions. Exp. Appl. Acarol. 1989, 7, 59–69. [Google Scholar] [CrossRef]
  73. Stone, B.F.; Youlton, N.J. Inheritance of resistance to chlorpyrifos in the Mt Alford strain and to diazinon in the Gracemere strain of the cattle tick (Boophilus microplus). Aust. J. Biol. Sci. 1982, 35, 427–440. [Google Scholar] [CrossRef] [PubMed]
  74. Stone, B.F.; Nolan, J.; Schuntner, C.A. Biochemical genetics of resistance to organophosphorus acaricides in three strains of the cattle tick, Boophilus Microplus. Aust. J. Biol. Sci. 1976, 29, 265–279. [Google Scholar] [CrossRef]
  75. Schnitzerling, H.J.; Stone, B.F. Loss of toxicity to cattle ticks of a wettable powder formulation of coumaphos. Aust. Vet. J. 1968, 44, 7–10. [Google Scholar] [CrossRef]
  76. Gough, J.M.; Kemp, D.H. Localization of a low abundance membrane protein (Bm86) on the gut cells of the cattle tick Boophilus microplus by immunogold labeling. J. Parasitol. 1993, 79, 900–907. [Google Scholar] [CrossRef] [PubMed]
  77. Allen, J.R.; Kemp, D.H. Observations on the behaviour of Dermacentor andersoni larvae infesting normal and tick resistant guinea-pigs. Parasitology 1982, 84 Pt 2, 195–204. [Google Scholar] [CrossRef]
  78. Allen, J.R.; Doube, B.M.; Kemp, D.H. Histology of bovine skin reactions to Ixodes holocyclus Neumann. Can. J. Comp. Med. 1977, 41, 26–35. [Google Scholar] [PubMed]
  79. Kemp, D.H.; Bird, P.E. Paralysis of calves by the tick, Ixodes Holocyclus. Aust. Vet. J. 1977, 53, 39–43. [Google Scholar] [CrossRef] [PubMed]
  80. Gough, J.M.; Kemp, D.H.; Akhurst, R.J.; Pearson, R.D.; Kongsuwan, K. Identification and characterization of proteins from Bacillus thuringiensis with high toxic activity against the sheep blowfly, Lucilia Cuprina. J. Invertebr. Pathol. 2005, 90, 39–46. [Google Scholar] [CrossRef]
  81. Paine, S.H.; Kemp, D.H.; Allen, J.R. In vitro feeding of Dermacentor andersoni (Stiles): Effects of histamine and other mediators. Parasitology 1983, 86 Pt 3, 419–428. [Google Scholar] [CrossRef]
  82. Allingham, P.G.; East, I.J.; Kerlin, R.L.; Kemp, D.H. Digestion of host immunoglobulin and activity of midgut proteases in the buffalo fly Haematobia irritans exigua. J. Insect Physiol. 1998, 44, 445–450. [Google Scholar] [CrossRef]
  83. Tabor, A.E. The enigma of identifying new cattle tick vaccine antigens. In Tick and Tick-Borne Pathogens; InTechOpen: London, UK, 2018. [Google Scholar]
  84. Schetters, T.P.M.; Jansen, T. Vaccine Against Rhipicephalus Ticks. WO2014154847A1, 2 October 2014. [Google Scholar]
  85. Almazan, C.; Kocan, K.; Bergman, D.; Garcia-Garcia, J.; Blouin, E.; de la Fuente, J. Identification of protective antigens for the control of Ixodes scapularis infestations using cDNA expression library immunization. Vaccine 2003, 21, 1492–1501. [Google Scholar] [CrossRef]
  86. Merino, O.; Antunes, S.; Mosqueda, J.; Moreno-Cid, J.A.; Pérez de la Lastra, J.M.; Rosario-Cruz, R.; Rodríguez, S.; Domingos, A.; de la Fuente, J. Vaccination with proteins involved in tick–pathogen interactions reduces vector infestations and pathogen infection. Vaccine 2013, 31, 5889–5896. [Google Scholar] [CrossRef]
  87. Song, J.; He, Q.-F. Bioinformatics analysis of the structure and linear B–cell epitopes of aquaporin–3 from Schistosoma japonicum. Asian Pac. J. Trop. Med. 2012, 5, 107–109. [Google Scholar] [CrossRef] [Green Version]
  88. Guerrero, F.D.; Andreotti, R.; Bendele, K.G.; Cunha, R.C.; Miller, R.J.; Yeater, K.; Pérez de León, A.A. Rhipicephalus (Boophilus) microplus aquaporin as an effective vaccine antigen to protect against cattle tick infestations. Parasit. Vectors 2014, 7, 475–487. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  89. Rodríguez-Mallon, A.; Encinosa, P.E.; Méndez-Pérez, L.; Bello, Y.; Rodríguez Fernández, R.; Garay, H.; Cabrales, A.; Méndez, L.; Borroto, C.; Estrada, M.P. High efficacy of a 20 amino acid peptide of the acidic ribosomal protein P0 against the cattle tick, Rhipicephalus Microplus. Ticks Tick Borne Dis. 2015, 6, 530–537. [Google Scholar] [CrossRef] [PubMed]
  90. Gong, H.; Liao, M.; Zhou, J.; Hatta, T.; Huang, P.; Zhang, G.; Kanuka, H.; Nishikawa, Y.; Xuan, X.; Fujisaki, K. Gene silencing of ribosomal protein P0 is lethal to the tick Haemaphysalis longicornis. Vet. Parasitol. 2008, 151, 268–278. [Google Scholar] [CrossRef] [PubMed]
  91. Hajdusek, O.; Almazán, C.; Loosova, G.; Villar, M.; Canales, M.; Grubhoffer, L.; Kopacek, P.; de la Fuente, J. Characterization of ferritin 2 for the control of tick infestations. Vaccine 2010, 28, 2993–2998. [Google Scholar] [CrossRef]
  92. de la Fuente, J.; Estrada-Peña, A. Why new vaccines for the control of ectoparasite vectors have not been registered and commercialized? Vaccines 2019, 7, 75. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Table
Table 1. Summary of tick vaccine research in Australia—the Australian cattle tick Rhipicephalus australis and the Australian paralysis tick Ixodes holocyclus.
Table 1. Summary of tick vaccine research in Australia—the Australian cattle tick Rhipicephalus australis and the Australian paralysis tick Ixodes holocyclus.
Target SpeciesGroupOutputsReferences
Rhipicephalus australisCSIRO Demonstrated protection from challenge using crude gut extracts; Isolation of gut protein Bm86 and demonstrated protection from challenge using native protein; Patent filing in 1985/1986, followed by commercial development and release of TickGARD® (1994) and TickGARD®PLUS (1995)[21,22,23]
UQ Demonstrated protection from challenge using midgut membrane extracts; Demonstration that gut membrane extracts are protective compared to soluble antigens; Showed that IgG1 and complement antibodies correlated with protection[24,25]
Beef CRC/MLA Reverse vaccinology pipeline was developed to identify novel tick vaccine antigens; Full patents filed February 2018; Antigens under Intellectual Property protection, data unpublished[7,26]
Ixodes holocyclusCSIRO Developed paralysis tick toxoid for anti-toxin activity demonstrated in rabbits; Artificial feeding methods for the collection of paralysing toxin; Development of a suckling mouse toxin/anti-toxin assay; Protection shown in dogs[15,27,28,29,30]
University of Technology Sydney Isolated three polypeptides bound to synaptosomes; Successfully sequenced and expressed holocyclotoxin-1 (HT-1) in E. coli[31,32]
UQ Transcriptome sequence database prepared from feeding adult female tick guts and salivary glands; Based on HT-1 homology, a diverse family of 19 HTs was identified; Proof of concept dog trial with a cocktail of synthetic HTs; Full patent submitted October 2017; Data unpublished[16]
Table
Table 2. Summary of Bm86 efficacies relative to TickGARD® strain R. australis Yeerongpilly—modified from Willadsen 2008 [23], including additions for the USA, Columbia and Brazil.
Table 2. Summary of Bm86 efficacies relative to TickGARD® strain R. australis Yeerongpilly—modified from Willadsen 2008 [23], including additions for the USA, Columbia and Brazil.
R. microplus IsolateSequence DifferenceEfficacyReferences
R. australis Indooroopilly Y (Australia)0%89%[36]
R. microplus Tuxpan (Mexico)5.7%51%[37]
R. microplus Mora (Mexico)8.6%58%[37]
R. microplus (Mexico)3.3%89%[38] 1
R. microplus (Argentina)1.6%10%[37]
R. microplus Camcord GAVAC strain (Cuba)0.2%84%[39,40,41]
R. microplus (Columbia)unpublished81%[42]
R. microplus Texas (USA)10.2%50–65%[43,44]
R. microplus Campo Grande (Brazil)3.5%31%[45,46]
1 Cited by Willadsen [23]; article not accessible for this review.
Table
Table 3. Anti-tick antigens developed and tested by CSIRO after Bm86 registration.
Table 3. Anti-tick antigens developed and tested by CSIRO after Bm86 registration.
Antigen DescriptionTesting RegimePublished EfficacyReferences
Bm91/Angiotensin-converting enzyme-like/CarboxypeptidaseBm86 + Bm91, tested in cattle7% reduction in egg viability[48,49,50]
BMA7/Mucin-like glycoproteinBMA7; Bm86+BMA7, tested in cattle21% reduction in egg weights; doubled efficacy when mixed with Bm86[51]
GP80/VIT87 Vitellin/VitellogeninTested in sheep66–68% reduction in tick larvae (native protein); 0% efficacy (recombinant)[52]
5′ nucleotidase/Apyrase5′ nucleotidase; Bm86 + 5′ nucleotidase, tested in sheep and cattleNo efficacy (cattle)[53]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Tabor, A.E. A Review of Australian Tick Vaccine Research. Vaccines 2021, 9, 1030. https://doi.org/10.3390/vaccines9091030

AMA Style

Tabor AE. A Review of Australian Tick Vaccine Research. Vaccines. 2021; 9(9):1030. https://doi.org/10.3390/vaccines9091030

Chicago/Turabian Style

Tabor, Ala E. 2021. "A Review of Australian Tick Vaccine Research" Vaccines 9, no. 9: 1030. https://doi.org/10.3390/vaccines9091030

APA Style

Tabor, A. E. (2021). A Review of Australian Tick Vaccine Research. Vaccines, 9(9), 1030. https://doi.org/10.3390/vaccines9091030

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop